Reuters logo
6 个月前
BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax
2017年2月27日 / 上午10点02分 / 6 个月前

BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax

1 分钟阅读

Feb 27 (Reuters) - Abbvie Inc

* Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

* Less than one percent of patients experienced serious adverse events or clinically significant laboratory abnormalities Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below